According to the International Diabetes Federation (IDF), approximately 425 million people had diabetes in 2017, and this number is estimated to reach 629 million by 2045. Cancer, which has become the leading cause of death globally, accounted for 9.6 million deaths in 2018. According to GLOBOCAN, the number of cancer cases will rise to approximately 30 million by 2040 from 18 million in 2018. The growth in the prevalence of these diseases has resulted in a need to conduct extensive research for their diagnosis and treatment; cell expansion forms an important part of this research.
Research in cell biology necessitates the use of animals and humans, as animal and human cells are used in gene therapy studies that involve the recombination of genes and stem cell research therapies. These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs, which may harm animals and humans.
These ethical concerns and restrictions on the use of cells for research are limiting cell biology research to a great extent in various countries across the globe. This, in turn, is expected to restrict the growth of the cell expansion market.
For More Information Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194978883
Growth in the biotechnology and pharmaceutical industries in these countries is expected to increase the demand for cell expansion products for R&D and the production of pharmaceutical products.
The regenerative medicine and stem cell research segment accounted for the largest market share in 2019 due to the increased funding for regenerative medicine and stem cell research.
The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.
Research Developments Analysis
1. In 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division. The division will be known as Cytiva and act as a standalone operating company within Danaher's Life Sciences segment.
2. In 2020, Eppendorf Group is expanding its production capacity at its Oldenburg, Holstein site in Germany. Due to the growing demand for consumables for COVID-19 research, the company will be manufacturing consumables made of high-quality plastic, such as pipette tips and tubes and single-use bioreactor vessels, at the newly expanded site.
3. In 2020, Applikon Biotechnology entered into a partnership with Sotelab to strengthen its presence in the advanced cultivation systems market in South America.
4. In 2019, Thermo Fisher Scientific invested around USD 24 million in its Inchinnan, Scotland site to expand global bio-production capabilities with additional large-volume liquid manufacturing capacity for cell culture media to meet growing customer demand.